Open AccessPalliative benefits of the multimodality approach in the re-treatment of recurrent malignant glioma: Two case reports
Author(s) -
Arulponni Tr,
MG Janaki,
S Nirmala
Publication year - 2009
Publication title -
indian journal of palliative care/indian journal of palliative care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 26
eISSN - 1998-3735
pISSN - 0973-1075
DOI - 10.4103/0973-1075.58464
Subject(s) - temozolomide , medicine , glioma , adjuvant , surgery , body surface area , palliative treatment , radiation therapy , cancer research
Two young male patients treated seven and four years back, for malignant glioma, returned with recurrence at the same site, with a World Health Organization (WHO) Performance Score of four and two. Both underwent resurgery and received postoperative reirradiation of 5040 cGy in 28 fractions and concurrent Temozolomide 75 mg/m(2) body surface area (BSA) daily, and one patient received additional adjuvant Temozolomide 250 mg (150 mg/m(2) BSA). Both patients tolerated the treatment well with 16 and 14 months follow-up from the time of recurrence. They were symptom-free, with normal physical function and good mental state, and resumed their respective jobs.